These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 27831504)
21. Correspondence re L. J. Wirth et al., Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a phase I study. Clin Cancer Res 2003;9:1698-704. Cesario A; Margaritora S; Galetta D; Porziella V; Granone P; D'Angelillo RM; Trodella L; Cardaci V; Sterzi S; Russo P Clin Cancer Res; 2004 Apr; 10(8):2902-3; author reply 2904. PubMed ID: 15102699 [No Abstract] [Full Text] [Related]
22. Ifosfamide and docetaxel in non-small cell lung cancer. Drings P; Büchholz E; Manegold C Semin Oncol; 1998 Feb; 25(1 Suppl 2):29-37. PubMed ID: 9535209 [TBL] [Abstract][Full Text] [Related]
23. Gefitinib plus docetaxel in non-small-cell lung cancer. Singh N; Aggarwal AN Lancet; 2009 Feb; 373(9663):541-2; author reply 542. PubMed ID: 19217980 [No Abstract] [Full Text] [Related]
24. [Docetaxel (taxotere) in non-small-cell bronchial carcinoma]. Manegold C Med Klin (Munich); 1997 Sep; 92 Suppl 4():10-5. PubMed ID: 9446014 [TBL] [Abstract][Full Text] [Related]
25. Nintedanib for the treatment of patients with advanced non-small-cell lung cancer. Reck M; Heigener D; Reinmuth N Expert Rev Clin Pharmacol; 2014 Sep; 7(5):579-90. PubMed ID: 25119062 [TBL] [Abstract][Full Text] [Related]
26. [Docetaxel in neoadjuvant therapy of early-stage non-small cell carcinoma]. Betticher DC Onkologie; 2003 Dec; 26 Suppl 7():33-6. PubMed ID: 14716140 [TBL] [Abstract][Full Text] [Related]
28. First-line chemotherapy for advanced-stage non-small-cell lung cancer: focus on docetaxel. Ramalingam S Clin Lung Cancer; 2005 Dec; 7 Suppl 3():S77-82. PubMed ID: 16384540 [TBL] [Abstract][Full Text] [Related]
29. Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial. Peters S; Stahel RA; Dafni U; Ponce Aix S; Massutí B; Gautschi O; Coate L; López Martín A; van Heemst R; Berghmans T; Meldgaard P; Cobo Dols M; Garde Noguera J; Curioni-Fontecedro A; Rauch D; Mark MT; Cuffe S; Biesma B; van Henten AMJ; Juan Vidal Ó; Palmero Sanchez R; Villa Guzmán JC; Collado Martin R; Peralta S; Insa A; Summers Y; Láng I; Horgan A; Ciardiello F; de Hosson S; Pieterman R; Groen HJM; van den Berg PM; Zielinski CC; Chittazhathu Kurian Kuruvilla Y; Gasca-Ruchti A; Kassapian M; Novello S; Torri V; Tsourti Z; Gregorc V; Smit EF; J Thorac Oncol; 2017 Apr; 12(4):752-762. PubMed ID: 28017787 [TBL] [Abstract][Full Text] [Related]
30. Brief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy. Ng R; Loreto M; Lee R; Leighl NB Lung Cancer; 2008 Aug; 61(2):262-5. PubMed ID: 18358559 [TBL] [Abstract][Full Text] [Related]
31. Docetaxel in the management of advanced non-small cell lung cancer. Miller VA Semin Oncol; 1998 Jun; 25(3 Suppl 8):15-9. PubMed ID: 9704671 [TBL] [Abstract][Full Text] [Related]
32. New perspectives in the second-line treatment of non squamous NSCLC patients: Results from a large Italian Lung Cancer Working Group. Cortinovis D; Gregorc V; Migliorino MR; Abate MI; Manzo A; Malapelle U; Morabito A; Crit Rev Oncol Hematol; 2017 Jan; 109():35-41. PubMed ID: 28010896 [TBL] [Abstract][Full Text] [Related]
33. [A randomized control clinical trial of Euruikang (docetaxel) in treatment of advanced non-small cell lung cancer (NSCLC)]. Cao Y; Wang ZQ; Guo Y; Feng FY; Hu XH; Xiong JP; Tang GD; Guan ZZ; Zhang L Ai Zheng; 2006 Aug; 25(8):999-1002. PubMed ID: 16965682 [TBL] [Abstract][Full Text] [Related]
34. [Docetaxel and novel strategies in the treatment of NSCLC]. Longo F; Mansueto G Tumori; 2005; 91(6):suppl 11-22. PubMed ID: 16457162 [No Abstract] [Full Text] [Related]
35. Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial. Pectasides D; Pectasides M; Farmakis D; Kostopoulou V; Nikolaou M; Gaglia A; Koumpou M; Mylonakis N; Xiros N; Economopoulos T; Raptis SA Ann Oncol; 2005 Feb; 16(2):294-9. PubMed ID: 15668287 [TBL] [Abstract][Full Text] [Related]
37. [Efficacy and safety of rh-endostatin combined with docetaxel in second-line or intolerant toxicity for first-line treatment in patients with advanced non-small cell lung cancer]. Wang J; Li K; Sun T; Zhang MJ; Li WL; Yao Q; Liu W; Ding CM; He ZY; Mao WD; Wang HM; Zhang Y; Zhou XL Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):618-22. PubMed ID: 24314222 [TBL] [Abstract][Full Text] [Related]
38. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Camps C; Massuti B; Jiménez A; Maestu I; Gómez RG; Isla D; González JL; Almenar D; Blasco A; Rosell R; Carrato A; Viñolas N; Batista N; Girón CG; Galán A; López M; Blanco R; Provencio M; Diz P; Felip E; Ann Oncol; 2006 Mar; 17(3):467-72. PubMed ID: 16371411 [TBL] [Abstract][Full Text] [Related]
39. A randomised phase II study of docetaxel/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group trial (ATOM 019). Belvedere O; Follador A; Rossetto C; Merlo V; Defferrari C; Sibau AM; Aita M; Dal Bello MG; Meduri S; Gaiardo M; Fasola G; Grossi F Eur J Cancer; 2011 Jul; 47(11):1653-9. PubMed ID: 21514147 [TBL] [Abstract][Full Text] [Related]
40. A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients. Ohe Y; Niho S; Kakinuma R; Kubota K; Ohmatsu H; Goto K; Nokihara H; Kunitoh H; Saijo N; Aono H; Watanabe K; Tango M; Yokoyama A; Nishiwaki Y Ann Oncol; 2004 Jan; 15(1):45-50. PubMed ID: 14679118 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]